000309980 001__ 309980
000309980 005__ 20260220160031.0
000309980 0247_ $$2doi$$a10.2967/jnumed.125.271135
000309980 0247_ $$2pmid$$apmid:41714122
000309980 0247_ $$2ISSN$$a0097-9058
000309980 0247_ $$2ISSN$$a0022-3123
000309980 0247_ $$2ISSN$$a0161-5505
000309980 0247_ $$2ISSN$$a1535-5667
000309980 0247_ $$2ISSN$$a2159-662X
000309980 037__ $$aDKFZ-2026-00406
000309980 041__ $$aEnglish
000309980 082__ $$a610
000309980 1001_ $$aLanzafame, Helena$$b0
000309980 245__ $$a90Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis.
000309980 260__ $$aNew York, NY$$bSoc.$$c2026
000309980 3367_ $$2DRIVER$$aarticle
000309980 3367_ $$2DataCite$$aOutput Types/Journal article
000309980 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1771599618_3240620
000309980 3367_ $$2BibTeX$$aARTICLE
000309980 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000309980 3367_ $$00$$2EndNote$$aJournal Article
000309980 500__ $$aepub
000309980 520__ $$aFibroblast activation protein (FAP) is highly expressed in many cancers, especially sarcomas, and represents a promising theranostic target. We present an updated retrospective analysis of 90Y-FAP inhibitor (FAPI)-46 treatment in patients with sarcoma or other solid tumors. Methods: We performed monocentric analysis of patients with progressive sarcoma or metastatic cancer who were eligible for 90Y-FAPI-46 therapy after approved treatments had been exhausted and who showed high FAP expression (SUVmax, ≥10 in over 50% of lesions on 68Ga-FAPI-46 PET). After therapy, 90Y-FAPI-46 scintigraphy confirmed distribution and uptake, and serial 90Y-FAPI-46 PET/CT scans measured absorbed doses. Adverse events were graded by Common Terminology Criteria for Adverse Events version 5.0. Tumor responses were evaluated using RECIST and PERCIST. Results: Thirty patients-23 (77%) with sarcoma, 3 (10%) with pancreatic cancer, 1 (3%) with prostate cancer, 1 (3%) with gastric cancer, 1 (3%) with nonmelanoma skin cancer, and 1 (3%) with cholangiocarcinoma-received a total of 77 cycles of 90Y-FAPI-46 radiopharmaceutical therapy between June 2020 and December 2023 and were followed until death or the last follow-up (April 2024). The median interval between cycles was 5 mo (interquartile range [IQR], 4 mo). Of the 30 patients, 11 (37%) received 4 or more cycles. A median of 3.7 GBq (IQR, 3.7-3.8 GBq) was administered during the first cycle, and a median of 7.4 GBq (IQR, 7.2-7.4 GBq) was administered for subsequent cycles. The mean absorbed dose was 0.48 Gy/GBq (SD, 0.06 Gy/GBq) in the kidneys and 0.04 Gy/GBq (SD, 0.01 Gy/GBq) in the bone marrow. Lesions with the highest uptake absorbed a mean dose of 2.4 Gy/GBq (SD, 1.04 Gy/GBq). After treatment, hematotoxicity of any grade was observed in 20 of 30 (67%) patients. Eight of 30 (27%) patients reached a Common Terminology Criteria for Adverse Events grade of at least 3, experiencing adverse events that included thrombocytopenia in 2 (6%), neutropenia in 2 (6%), anemia in 2 (6%), leukopenia in 1 (3%), and elevated γ-glutamyl transferase in 1 (3%) patient. RECIST (n = 25) and PERCIST (n = 20) responses after treatment were assessed. Disease control according to RECIST was 48% (12/25), including 3 partial responses (12%). Disease control correlated with extended overall survival (median, 14.6 vs. 1.9 mo). Metabolic response per PERCIST was observed in 12 of 20 (60%) patients. Conclusion: With long-term follow-up, the favorable safety profile of 90Y-FAPI-46 therapy is confirmed. Nearly half of the patients demonstrated disease stabilization, almost exclusively in sarcomas. Our findings support the role of FAP-directed radiopharmaceutical therapy in patients with metastatic sarcoma.
000309980 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000309980 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000309980 650_7 $$2Other$$a90Y-FAPI-46
000309980 650_7 $$2Other$$aradiopharmaceutical therapy
000309980 650_7 $$2Other$$asarcomas
000309980 650_7 $$2Other$$atheranostics
000309980 7001_ $$aMavroeidi, Ilektra A$$b1
000309980 7001_ $$aPabst, Kim M$$b2
000309980 7001_ $$aFragoso Costa, Pedro$$b3
000309980 7001_ $$aSchuler, Martin$$b4
000309980 7001_ $$aBauer, Sebastian$$b5
000309980 7001_ $$aKurth, Jens$$b6
000309980 7001_ $$aHeuschkel, Martin$$b7
000309980 7001_ $$0P:(DE-He78)026e0a55b968f360a3c349689ce8a99c$$aSiveke, Jens T$$b8$$udkfz
000309980 7001_ $$aHerrmann, Ken$$b9
000309980 7001_ $$aKostbade, Karina$$b10
000309980 7001_ $$aKersting, David$$b11
000309980 7001_ $$aLeyser, Stephan$$b12
000309980 7001_ $$0P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aFröhling, Stefan$$b13
000309980 7001_ $$0P:(DE-He78)42b6114cd48e033299b2b6ef4bf56cc6$$aHeilig, Christoph E$$b14$$udkfz
000309980 7001_ $$aHamacher, Rainer$$b15
000309980 7001_ $$aFendler, Wolfgang P$$b16
000309980 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.125.271135$$gp. jnumed.125.271135 -$$pnn$$tJournal of nuclear medicine$$vnn$$x0097-9058$$y2026
000309980 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)026e0a55b968f360a3c349689ce8a99c$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000309980 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000309980 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)42b6114cd48e033299b2b6ef4bf56cc6$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000309980 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000309980 9141_ $$y2026
000309980 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-10
000309980 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-10
000309980 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2025-11-10
000309980 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-10
000309980 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-10
000309980 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-11-10
000309980 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-10
000309980 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-10
000309980 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-10
000309980 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-11-10
000309980 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-11-10
000309980 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2022$$d2025-11-10
000309980 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NUCL MED : 2022$$d2025-11-10
000309980 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000309980 9201_ $$0I:(DE-He78)B340-20160331$$kB340$$lTranslationale Medizinische Onkologie$$x1
000309980 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000309980 980__ $$ajournal
000309980 980__ $$aVDB
000309980 980__ $$aI:(DE-He78)ED01-20160331
000309980 980__ $$aI:(DE-He78)B340-20160331
000309980 980__ $$aI:(DE-He78)HD01-20160331
000309980 980__ $$aUNRESTRICTED